Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update

Chimerix, Inc. (NASDAQ:CMRX) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 1,320,000 shares, a growth of 6.5% from the March 31st total of 1,240,000 shares. Approximately 1.7% of the shares of the company are sold short. Based on an average daily trading volume, of 419,700 shares, the days-to-cover ratio is presently 3.1 days.

Chimerix Price Performance

NASDAQ:CMRX opened at $0.95 on Thursday. Chimerix has a 12 month low of $0.88 and a 12 month high of $1.57. The business’s 50-day moving average is $1.05 and its two-hundred day moving average is $1.00.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 37.93%. As a group, equities research analysts predict that Chimerix will post -0.77 EPS for the current year.

Institutional Investors Weigh In On Chimerix

A number of institutional investors have recently made changes to their positions in CMRX. Assenagon Asset Management S.A. raised its holdings in shares of Chimerix by 17.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 499,391 shares of the biopharmaceutical company’s stock worth $481,000 after purchasing an additional 72,719 shares during the period. Bank of New York Mellon Corp lifted its holdings in Chimerix by 190.0% in the third quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock worth $568,000 after acquiring an additional 387,638 shares during the last quarter. Vance Wealth Inc. acquired a new position in Chimerix in the fourth quarter valued at approximately $46,000. Pale Fire Capital SE bought a new position in shares of Chimerix during the third quarter valued at approximately $95,000. Finally, RA Capital Management L.P. bought a new position in shares of Chimerix during the third quarter valued at approximately $6,240,000. 45.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Chimerix in a research report on Friday, March 1st. StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research report on Monday, March 4th. Finally, Wedbush restated an “outperform” rating and set a $6.00 target price on shares of Chimerix in a report on Monday, February 12th.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.